Between 2014 and 2018, 43 patients with locally advanced rectal cancer completed neoadjuvant concurrent chemoradiotherapy, had a restaging MRI, and underwent surgery. Weighted kappa was used to test the agreement between yT and yN with ypT and ypN, respectively. A kappa value of less than 0.5 was deemed unacceptable. Paired t test was used to compare NAR and mNAR mean scores. Survival was estimated by Kaplan-Meier curves.
Restaging MRI could not predict ypT stage (slight agreement, κ = 0.111) or ypN stage (fair agreement, κ = 0.278). The mean mNAR score was higher than the mean NAR score (20 vs. 16, P = .0079). The median DFS for patients with low-intermediate NAR and high NAR was not reached vs. 30 months (P = .0063). The median OS for patients with low-intermediate NAR and high NAR was not reached vs. 40 months (P = .0056). There was a trend for longer DFS and OS in patients with low-intermediate mNAR scores (not reached in both groups, P = .058) compared to patients with high mNAR scores (not reached in both groups, P = .15).
Restaging MRI could not predict ypT and ypN stage. The mean mNAR score was higher than the mean NAR score. There was a trend for longer DFS and OS in patients with low-intermediate mNAR scores compared to patients with high mNAR scores.
2014年至2018年,43例局部晚期直肠癌患者完成了新辅助同步放化疗,重新做了核磁共振,接受了手术.用加权κ检验yT和yN与ypT和ypN的一致性,分别。小于0.5的kappa值被认为是不可接受的。采用配对t检验比较NAR和mNAR均分。通过Kaplan-Meier曲线估计存活率。
重新MRI无法预测ypT分期(轻微一致,κ=0.111)或ypN阶段(公平协议,κ=0.278)。平均mNAR评分高于平均NAR评分(20vs.16,P=.0079)。低-中NAR和高NAR患者的中位DFS未达到。30个月(P=0.0063)。低-中NAR和高NAR的患者的中位OS未达到与40个月(P=0.0056)。在mNAR评分较低至中等的患者中,有DFS和OS较长的趋势(两组均未达到,P=0.058)与高mNAR评分的患者相比(两组均未达到,P=.15)。
重新进行MRI无法预测ypT和ypN分期。平均mNAR评分高于平均NAR评分。与具有高mNAR评分的患者相比,具有低-中等mNAR评分的患者存在较长DFS和OS的趋势。